- Home
- OLMA
as of 04-01-2026 3:59pm EST
Olema Pharmaceuticals inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of next generation targeted therapies for women's cancers. Its therapies offer the potential to improve outcomes for women living with cancer. The company has completed discovery and preclinical studies of OP-1250. OP-3136 is another drug candidate in the company's product pipeline.
| Founded: | 2006 | Country: | United States |
| Employees: | N/A | City: | SAN FRANCISCO |
| Market Cap: | 1.2B | IPO Year: | 2020 |
| Target Price: | $44.89 | AVG Volume (30 days): | 1.7M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 10 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.87 | EPS Growth: | 15.00 |
| 52 Week Low/High: | $2.86 - $36.26 | Next Earning Date: | 03-16-2026 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | 347.47% |
| P/E Ratio: | -7.97 | Index: | N/A |
| Free Cash Flow: | -146875000.0 | FCF Growth: | N/A |
AI-Powered OLMA Daily Prediction
Machine learning model trained on 25+ technical indicators
AI Recommendation
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of Olema Pharmaceuticals Inc. (OLMA)
CHIEF LEGAL OFFICER
Avg Cost/Share
$24.47
Shares
25,000
Total Value
$606,352.52
Owned After
233
CHIEF LEGAL OFFICER
Avg Cost/Share
$23.01
Shares
15,000
Total Value
$345,150.00
Owned After
233
SEC Form 4
Director
Avg Cost/Share
$26.88
Shares
10,000
Total Value
$268,800.00
Owned After
727,770
SEC Form 4
CH. OPERATING & FINANCIAL OFF.
Avg Cost/Share
$28.73
Shares
100,000
Total Value
$2,873,000.00
Owned After
139,727
SEC Form 4
CH. DISCOV. & NON-CLIN DEV OFF
Avg Cost/Share
$28.80
Shares
50,000
Total Value
$1,443,651.17
Owned After
542,761
CH. DISCOV. & NON-CLIN DEV OFF
Avg Cost/Share
$28.05
Shares
50,000
Total Value
$1,380,178.00
Owned After
542,761
CH. OPERATING & FINANCIAL OFF.
Avg Cost/Share
$28.01
Shares
3,822
Total Value
$107,054.22
Owned After
139,727
SEC Form 4
CH. DISCOV. & NON-CLIN DEV OFF
Avg Cost/Share
$28.34
Shares
10,000
Total Value
$283,400.00
Owned After
542,761
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Mitchell Shawnte | OLMA | CHIEF LEGAL OFFICER | Mar 4, 2026 | Sell | $24.47 | 25,000 | $606,352.52 | 233 | |
| Mitchell Shawnte | OLMA | CHIEF LEGAL OFFICER | Mar 3, 2026 | Sell | $23.01 | 15,000 | $345,150.00 | 233 | |
| Harmon Cyrus | OLMA | Director | Jan 20, 2026 | Sell | $26.88 | 10,000 | $268,800.00 | 727,770 | |
| Kovacs Shane William Charles | OLMA | CH. OPERATING & FINANCIAL OFF. | Jan 15, 2026 | Sell | $28.73 | 100,000 | $2,873,000.00 | 139,727 | |
| Myles David C. | OLMA | CH. DISCOV. & NON-CLIN DEV OFF | Jan 14, 2026 | Sell | $28.80 | 50,000 | $1,443,651.17 | 542,761 | |
| Myles David C. | OLMA | CH. DISCOV. & NON-CLIN DEV OFF | Jan 13, 2026 | Sell | $28.05 | 50,000 | $1,380,178.00 | 542,761 | |
| Kovacs Shane William Charles | OLMA | CH. OPERATING & FINANCIAL OFF. | Jan 13, 2026 | Sell | $28.01 | 3,822 | $107,054.22 | 139,727 | |
| Myles David C. | OLMA | CH. DISCOV. & NON-CLIN DEV OFF | Jan 12, 2026 | Sell | $28.34 | 10,000 | $283,400.00 | 542,761 |
Earnings Transcripts
SEC 8-K filings with transcript text
2025 Q4 Q4 2025 Earnings
8-K SELL Jan 12, 2026 · 100% conf.
Q4 2025 Earnings
8-K SELLJan 12, 2026 · 100% conf.
1D
-7.28%
$26.69
Act: -3.13%
5D
-12.17%
$25.29
Act: -7.19%
20D
+7.94%
$31.07
Act: -18.83%
8-K
0001750284false00017502842026-01-122026-01-12
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): January 12, 2026
Olema Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter)
Delaware
001-39712
30-0409740
(State or Other Jurisdiction of Incorporation)
(Commission File Number)
(IRS Employer Identification No.)
780 Brannan Street
San Francisco, California
94103
(Address of Principal Executive Offices)
(Zip Code)
Registrant’s Telephone Number, Including Area Code: 415 651-3316
N/A
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common Stock, par value $0.0001 per share
OLMA
The Nasdaq Global Select Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition.
On January 12, 2026, Olema Pharmaceuticals, Inc. (the "Company") announced that its preliminary unaudited cash, cash equivalents and marketable securities as of December 31, 2025 were greater than $500 million.
The Company has not yet completed its fiscal year-end financial close process for the year ended December 31, 2025. This estimate of the Company’s cash, cash equivalents and marketable securities as of December 31, 2025 is preliminary, unaudited, and is subject to change upon completion of the Company’s financial closing procedures. Additional information and disclosures would be required for a more complete understanding of the Company’s financial position and results of operations as of December 31, 2025. The Company’s independent registered public accounting firm has not audited, reviewed or performed any procedures with respect to this preliminary result and, accordingly, does not express an opinion or any other form of assurance about it. The information presented herein should not be considered a substitute for the financial information the Company files with the U.S. Securities and Exchange Commission (the "SEC") in its annual report on Form 10-K for the fiscal year ended December 31, 2025. The Company has no intention or obligation to update preliminary estimates of its cash, cash equivalents and marketable securities set forth above.
The information contained in this Current Report on Form 8-K under Item 2.02 is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section and will not be incorporated by reference in any filing by the Company under the Securities Act of 1933, as amended (the "Securities Act"), or the Exchange Act, unless specifically identified as being incorporated therein by reference.
Item 7.01 Regulation FD Disclosure.
On January 12, 2026, the Company made available on its website a copy of the Company’s presentation to be shared with investors and others from time to time. The presentation is being furnished as Exhibit 99.1 to this Current Report on Form 8-K.
The information in Exhibit 99.1 attached hereto is intended to be furnished and shall not be deemed "filed" for purposes of Section 18 of the Exchange Act or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act or the Exchange Act, except as expressly set forth by specific reference in such filing.
Forward-Looking Statements
Statements contained in this Current Report on Form 8-K, including the exhibit furnished herewith, regarding matters that are not historical facts are "forward-looking statements" within the meaning of Section 27A of the Securities Act and Section 21E of the Exchange Act. Words such a
2025 Q3 Q3 2025 Earnings
8-K Nov 10, 2025
Q3 2025 Earnings
8-KNov 10, 2025
8-K
0001750284false00017502842025-11-102025-11-10
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): November 10, 2025
Olema Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter)
Delaware
001-39712
30-0409740
(State or Other Jurisdiction of Incorporation)
(Commission File Number)
(IRS Employer Identification No.)
780 Brannan Street
San Francisco, California
94103
(Address of Principal Executive Offices)
(Zip Code)
Registrant’s Telephone Number, Including Area Code: 415 651-3316
N/A
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common Stock, par value $0.0001 per share
OLMA
The Nasdaq Global Select Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition. On November 10, 2025, Olema Pharmaceuticals, Inc. (the “Company”) reported its financial results for the quarter ended September 30, 2025. A copy of the press release is furnished pursuant to Item 2.02 as Exhibit 99.1 hereto and is incorporated herein by reference.
The information in Item 2.02, including the press release attached as Exhibit 99.1 hereto, is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended or the Exchange Act, except as expressly set forth by specific reference in such filing. Item 9.01 Financial Statements and Exhibits. (d) Exhibits.
Exhibit No.
Description
99.1
Press Release, dated November 10, 2025, of Olema Pharmaceuticals, Inc.
104
Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
OLEMA PHARMACEUTICALS, INC.
Date:
November 10, 2025
By:
/s/ Shane Kovacs
Shane Kovacs Chief Operating and Financial Officer
2025 Q2 Q2 2025 Earnings
8-K Aug 11, 2025
Q2 2025 Earnings
8-KAug 11, 2025
8-K
false000175028400017502842025-08-112025-08-11
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): August 11, 2025
Olema Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter)
Delaware
001-39712
30-0409740
(State or Other Jurisdiction of Incorporation)
(Commission File Number)
(IRS Employer Identification No.)
780 Brannan Street
San Francisco, California
94103
(Address of Principal Executive Offices)
(Zip Code)
Registrant’s Telephone Number, Including Area Code: 415 651-3316
N/A
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common Stock, par value $0.0001 per share
OLMA
The Nasdaq Global Select Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition. On August 11, 2025, Olema Pharmaceuticals, Inc. (the “Company”) reported its financial results for the quarter ended June 30, 2025. A copy of the press release is furnished pursuant to Item 2.02 as Exhibit 99.1 hereto and is incorporated herein by reference. Item 7.01 Regulation FD Disclosure. On August 11, 2025, the Company also made available on its website a copy of the Company’s presentation to be shared with investors and others from time to time. The presentation is being furnished as Exhibit 99.2 to this Current Report on Form 8-K.
The information in Item 2.02, including the press release attached as Exhibit 99.1 hereto, and in Exhibit 99.2 attached hereto is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended or the Exchange Act, except as expressly set forth by specific reference in such filing. Item 9.01 Financial Statements and Exhibits. (d) Exhibits.
Exhibit No.
Description
99.1
Press Release, dated August 11, 2025, of Olema Pharmaceuticals, Inc.
99.2
Investor Presentation, dated August 11, 2025, of Olema Pharmaceuticals, Inc.
104
Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
OLEMA PHARMACEUTICALS, INC.
Date:
August 11, 2025
By:
/s/ Shane Kovacs
Shane Kovacs Chief Operating and Financial Officer
Compare OLMA vs Leading Stocks
See how OLMA stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "OLMA Olema Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.